
|Videos|June 22, 2021
Pharmacist Medication Insights: Xembify for Primary Humoral Immunodeficiency Disease
Author(s)Saro Arakelians, PharmD
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Advertisement
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Xembify is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Stanford, Harvard, and Yale Are Betting on Psychedelics
2
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
3
Comprehensive Lancet Review Reaffirms Safety, Effectiveness of mRNA Vaccines
4
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
5










































































































